European organization for the research and treatment of cancer/mycoses study group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 8, 2012, Pages 2029-2033

  Hoenigl, Martin ^a   Strenger, Volker ^a   Buzina, Walter ^a   Valentin, Thomas ^a   Koidl, Christoph ^a   Wölfler, Albert ^a   Seeber, Katharina ^a   Valentin, Angelika ^a   Strohmeier, Anna T ^a   Zollner Schwetz, Ines ^a   Raggam, Reinhard B ^a   Urban, Christian ^a   Lass Flörl, Cornelia ^b   Linkesch, Werner ^a   Krause, Robert ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Allogeneic stem cell transplantation; Aspergillosis; Corticosteroid treatment; Fungi; Invasive mould infections

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; HOST FACTOR; PREDNISONE; SUPPRESSOR FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INVASIVE MOULD INFECTION; INVASIVE YEAST INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHEMOPREVENTION; EUROPE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84864516662     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks155     Document Type: Article

References (16)

1. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
2. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
3. Hoenigl M, Valentin T, Salzer HJ et al. Underestimating the real burden of invasive fungal infections in hematopoietic stem cell transplant recipients? Clin Infect Dis 2010; 51: 253-4; author reply 254-5.
4. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-9.
5. Hoenigl M, Zollner-Schwetz I, Sill H et al. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies. Mycoses 2011; 54: 454-9.
6. Hoenigl M, Salzer HJ, Raggam RB et al. Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies. Med Mycol 2012; 50: 266-9.
7. Valentin T, Neumeister P, Pichler M et al. Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD. Bone Marrow Transplant 2011; doi:10.1038/bmt.2011.149.
8. Hoenigl M, Raggam RB, Valentin T et al. Posaconazole plasma concentrations and invasive mould infections in patients with hematological malignancies. Int J Antimicrob Agents 2012; in press.
9. Agrawal S, Hope W, Sinko J et al. Optimizing management of invasive mould diseases. J Antimicrob Chemother 2011; 66 Suppl 1: i45-53.
10. Pagano L, Akova M, Dimopoulos G et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 2011; 66 Suppl 1: i5-14.
11. Erjavec Z, Kluin-Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect 2009; 15: 625-33.
12. Sun YQ, Xu LP, Liu DH et al. The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion. Clin Microbiol Infect 2011; doi:10.1111/j.1469-0691.2011.03697.x.
13. Tsiodras S, Samonis G, Boumpas DT et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83: 181-94.
14. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
15. Perkhofer S, Lass-Florl C, Hell M et al. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents 2010; 36: 531-6.
16. Thursky K, Byrnes G, Grigg A et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 115-21.